These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 7693081

  • 1. Cancer-associated serum globulin determined in patients with cervical, endometrial and ovarian cancer.
    Altarac S.
    Acta Med Croatica; 1993; 47(1):19-22. PubMed ID: 7693081
    [Abstract] [Full Text] [Related]

  • 2. Shed membrane fragment-associated markers for endometrial and ovarian cancers.
    Taylor DD, Lyons KS, Gerçel-Taylor C.
    Gynecol Oncol; 2002 Mar; 84(3):443-8. PubMed ID: 11855885
    [Abstract] [Full Text] [Related]

  • 3. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R, Stephens RW, Brünner N, Christensen IJ, Nielsen HJ, Heilmann L, von Tempelhoff GF.
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [Abstract] [Full Text] [Related]

  • 4. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors].
    Peng XP, Li JD, Li MD, Ye XM, Yan WC.
    Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072
    [Abstract] [Full Text] [Related]

  • 5. [Variations in the level of immunosuppressive acidic protein in patients with gynecologic tumors and pregnant women].
    Sawada M, Okudaira Y, Matsui Y, Miyoshi Y, Takayama K, Shimizu Y, Miura S.
    Gan To Kagaku Ryoho; 1983 Aug; 10(8):1823-30. PubMed ID: 6882005
    [Abstract] [Full Text] [Related]

  • 6. Serum evaluation of P53 protein in patients with gynaecological cancer.
    Barbati A, Mariani L, Porpora MG, Anceschi M, Collini P, Lauro V, Cosmi EV.
    Anticancer Res; 2000 Aug; 20(2A):1033-5. PubMed ID: 10810393
    [Abstract] [Full Text] [Related]

  • 7. Clinical significance of serum Dkk-3 in patients with gynecological cancer.
    Jiang T, Huang L, Wang S, Zhang S.
    J Obstet Gynaecol Res; 2010 Aug; 36(4):769-73. PubMed ID: 20666943
    [Abstract] [Full Text] [Related]

  • 8. [Immunosuppressive acidic protein in patients with gynecologic cancer].
    Sawada M, Matsui Y, Okudaira Y, Shimizu Y, Takayama K.
    Nihon Sanka Fujinka Gakkai Zasshi; 1983 May; 35(5):605-11. PubMed ID: 6408203
    [Abstract] [Full Text] [Related]

  • 9. [Serum levels of immunosuppressive acidic protein in gynecological cancer].
    Sato S, Wakisaka T, Hamazaki Y, Oikawa N, Toki T, Yamauchi R, Sakahira H, Tase T, Yajima A, Suzuki M.
    Gan No Rinsho; 1983 Jul; 29(8):897-9. PubMed ID: 6887522
    [Abstract] [Full Text] [Related]

  • 10. Initial experience with placental protein 4 (PP-4) as tumor marker in cervical and endometrial cancer.
    Göcze PM, Szabò DG, Than GN, Csaba IF, Keller G, Vahrson H, Bohn H.
    Strahlenther Onkol; 1991 Sep; 167(9):538-44. PubMed ID: 1833844
    [Abstract] [Full Text] [Related]

  • 11. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
    Ahmed N, Oliva KT, Barker G, Hoffmann P, Reeve S, Smith IA, Quinn MA, Rice GE.
    Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
    [Abstract] [Full Text] [Related]

  • 12. [Investigation of serum immunosuppresive acidic protein levels in gynecological tumor].
    Zhang W, Wang P, Zhao Y.
    Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):194-6. PubMed ID: 11601039
    [Abstract] [Full Text] [Related]

  • 13. Serum antibodies to the 27-kd heat shock protein in women with gynecologic cancers.
    Korneeva I, Bongiovanni AM, Girotra M, Caputo TA, Witkin SS.
    Am J Obstet Gynecol; 2000 Jul; 183(1):18-21. PubMed ID: 10920302
    [Abstract] [Full Text] [Related]

  • 14. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
    Suzuki H, Teshima K, Noda K.
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
    [Abstract] [Full Text] [Related]

  • 15. An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers.
    Konac E, Onen HI, Metindir J, Alp E, Biri AA, Ekmekci A.
    Cancer Detect Prev; 2007 Dec; 31(2):102-9. PubMed ID: 17418979
    [Abstract] [Full Text] [Related]

  • 16. Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data.
    Ferdeghini M, Gadducci A, Prontera C, Marrai R, Malagnino G, Annicchiarico C, Fioretti P, Bianchi R.
    Anticancer Res; 1993 Dec; 13(3):709-13. PubMed ID: 8317901
    [Abstract] [Full Text] [Related]

  • 17. Expression of high-abundance proteins in sera of patients with endometrial and cervical cancers: analysis using 2-DE with silver staining and lectin detection methods.
    Abdul-Rahman PS, Lim BK, Hashim OH.
    Electrophoresis; 2007 Jun; 28(12):1989-96. PubMed ID: 17503403
    [Abstract] [Full Text] [Related]

  • 18. [Regulation of ceruloplasmin activity in oncogynecological diseases].
    Gusarova IuN, Stepanova EV, Landesman EO, Koroleva OV, Vavilova TP, Makarov OV, Kosetskiĭ VN.
    Vopr Med Khim; 2002 Jun; 48(4):388-93. PubMed ID: 12506616
    [Abstract] [Full Text] [Related]

  • 19. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
    Nozawa S, Udagawa Y, Sasaki H, Ito K, Akiya K, Terashima Y, Takamizawa H, Ohkura H, Fujimoto S, Hashimoto M.
    Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
    [Abstract] [Full Text] [Related]

  • 20. [Significance of immunosuppressive acidic protein in the diagnosis and follow-up of patients with ovarian cancer, in particular as a marker for chemotherapeutic effects].
    Shimizu Y, Akagaki E, Hirota K, Kono M, Miura S, Okudaira Y, Kurachi K.
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Apr; 38(4):554-60. PubMed ID: 3701144
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.